XLO XILIO THERAPEUTICS INC Capital Structure Changes 8-K Filing 2025 - Stock Offering On March 11, 2025, Xilio Therapeutics entered into a Sales Agreement allowing it to sell up to $50 million of its common stock through Leerink Partners LLC, with the agent receiving 3% of the gross proceeds. The sales will occur at market prices on the Nasdaq Global Select Market, but there is no guarantee of sales or specific amounts.Get access to all SEC 8-K filings of the XILIO THERAPEUTICS INC